• Skip to main content
  • Skip to secondary menu
  • Skip to footer

Opinion.org

#Opinion: opinion matters

  • Sponsored Post
    • Make a Contribution
  • About
  • Contact

Wamberg Genomic Survey: 79% of Consumers Would Consider Genetic Testing to Limit Risk of Drug Side Effects

November 13, 2017 By Opinion.org Leave a Comment

Pharmacogenomics could help avert adverse drug reactions in about 2 million Americans per year that cause about 100,000 deaths.

Forty percent (40%) of consumers polled think that doctors can reduce the risk of drug side effects in patients through genetic testing, however almost double, 79%, would consider genetic testing, known as pharmacogenomics, to lower their own risk of experiencing drug side effects. Results are based on Wamberg Genomic Consumer Survey, which queried 536 U.S. consumers from 26 to 64 years old. Survey Sampling International (SSI) fielded the survey in October 2017.

The use of prescription drugs increases with age. Often, prescribed medications prove to be ineffective. In the US, serious adverse drug reactions are estimated to occur in about 2 million Americans a year and cause about 100,000 deaths per year, being one of the leading causes of death. Drug side effects also are costly being a significant cause of hospitalization.

The Wamberg Genomic Consumer Survey results are somewhat more favorable than the recent 2017 edition of The Sanofi Canada Healthcare Survey that showed that 67% of members of employee benefit plans report being interested in pharmacogenomic testing.

According to Dr. Phil Smalley, Chief Medical Director of Wamberg Genomic Advisors, “Pharmacogenomic testing allows doctors to prescribe the right drug, at the right dose to the right patient. Most people carry at least one actionable drug-gene variant that, if known, would mean a doctor should use a different drug or altered dose to treat that person. Truly, one size does not fit all.”

He explained that genetically guided prescribing makes drug therapy more effective and helps reduce serious drug side effects. Pharmacogenomic testing is now readily available and affordable.

In the Wamberg survey, respondents were asked:
If you were offered free genetic testing to limit the risk of drug side effects, would you want to get this testing now, whether or not you are currently on medications?

Yes 49%
Considering 30%
Not sure 13%
No 8%
Forty percent (40%) responded this statement was true: “Doctors can reduce the risk of drug side effects by looking at a person’s genetics before taking any medications.”

Other results of the survey revealed the following:

75% responded genetic testing can help people live a longer and better quality of life
33% have had genetic testing. Of those that have had testing, 52% found the results useful
Smalley added, “As more people get their drug-related genes tested, we believe that pharmacogenomics will become widespread. It allows doctors to reduce serious adverse drug reactions and prescribe more effective medications that will improve public health. In addition, it should help lower pharmaceutical costs by more effectively treating patients.”

About the Survey
The Wamberg Genomic Consumer Survey queried 536 U.S. consumers 26-64. The survey was fielded by Survey Sampling International (SSI) in October 2017. Data for the survey was collected via an opt-in panel. The margin of error was 4%.

About Survey Sampling International:
Survey Sampling International (SSI) has been the premier global provider of data solutions and technology for consumer and business-to-business survey research for 40 Years. For more information, go to www.surveysampling.com.

About Wamberg Genomic Advisors:
Wamberg Genomic Advisors’ mission to make genomic testing readily available at prices everyone can afford. Our focus is on delivering genomic products and services to employers and their employees via their trusted benefit brokers, and policyholders of life insurance companies. To learn more visit wamberggenomic.com.

Filed Under: Opinion Tagged With: Genomic Survey, Pharmacogenomics

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Footer

Recent Posts

  • Understanding the Concept of a Deep State
  • Bessent Urges Canada to Follow Mexico in Adopting China Tariffs
  • Europe’s Empty Words Will Not Save Ukraine
  • Zelensky Stands Firm Against White House Pressure
  • Shifting Trade Winds: The Uncertain Future of U.S.-China Economic Ties
  • Iran’s Strategic Dilemma After the Fall of Assad
  • The Unraveling of Putin’s Geopolitical Strategy in the Wake of Assad’s Fall
  • The Collapse of the Assad Regime: A Turning Point for Syria and the Region
  • Family of Journalist Dong Yuyu Condemns Espionage Conviction as a Grave Injustice
  • Putin’s Economic House of Cards: The Slow Collapse of a Despotic Gamble

Media Partners

  • Exclusive Domains
  • Press Media Release
  • Briefly
  • OPINT
  • VPNW
  • S3H
  • PressClub.US
  • Israel News

Media Partners

  • Technology Conferences
  • Event Sharing Network
  • Defense Conferences
  • Cybersecurity Events
  • Event Calendar
  • Calendarial
  • Domain Market Research

Copyright © 2015 Opinion.org

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
Cookie SettingsAccept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT